|
Name |
Peyronellin A
|
Molecular Formula | C28H36O7 | |
IUPAC Name* |
(1S,5R,6S)-6-[[(1S,4aR,5R,8aR)-5-(hydroxymethyl)-2,5,8a-trimethyl-1,4,4a,6,7,8-hexahydronaphthalen-1-yl]methyl]-5-hydroxy-3-[(4-hydroxy-6-methyl-2-oxopyran-3-yl)methyl]-7-oxabicyclo[4.1.0]hept-3-en-2-one
|
|
SMILES |
CC1=CC[C@H]2[C@](CCC[C@@]2([C@H]1C[C@]34[C@@H](C=C(C(=O)[C@H]3O4)CC5=C(C=C(OC5=O)C)O)O)C)(C)CO
|
|
InChI |
InChI=1S/C28H36O7/c1-15-6-7-21-26(3,14-29)8-5-9-27(21,4)19(15)13-28-22(31)12-17(23(32)24(28)35-28)11-18-20(30)10-16(2)34-25(18)33/h6,10,12,19,21-22,24,29-31H,5,7-9,11,13-14H2,1-4H3/t19-,21-,22+,24+,26-,27+,28-/m0/s1
|
|
InChIKey |
GMHDEOTYQHLKML-UKCWTKHPSA-N
|
|
Synonyms |
Peyronellin A; J3.515.441H
|
|
CAS | NA | |
PubChem CID | 132561489 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 484.6 | ALogp: | 2.9 |
HBD: | 3 | HBA: | 7 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 117.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 35 | QED Weighted: | 0.425 |
Caco-2 Permeability: | -4.978 | MDCK Permeability: | 0.00003830 |
Pgp-inhibitor: | 0.011 | Pgp-substrate: | 0.003 |
Human Intestinal Absorption (HIA): | 0.063 | 20% Bioavailability (F20%): | 0.994 |
30% Bioavailability (F30%): | 0.274 |
Blood-Brain-Barrier Penetration (BBB): | 0.227 | Plasma Protein Binding (PPB): | 94.01% |
Volume Distribution (VD): | 1.174 | Fu: | 5.10% |
CYP1A2-inhibitor: | 0.024 | CYP1A2-substrate: | 0.829 |
CYP2C19-inhibitor: | 0.2 | CYP2C19-substrate: | 0.796 |
CYP2C9-inhibitor: | 0.579 | CYP2C9-substrate: | 0.275 |
CYP2D6-inhibitor: | 0.022 | CYP2D6-substrate: | 0.694 |
CYP3A4-inhibitor: | 0.822 | CYP3A4-substrate: | 0.409 |
Clearance (CL): | 8.869 | Half-life (T1/2): | 0.77 |
hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.799 |
Drug-inuced Liver Injury (DILI): | 0.939 | AMES Toxicity: | 0.078 |
Rat Oral Acute Toxicity: | 0.828 | Maximum Recommended Daily Dose: | 0.183 |
Skin Sensitization: | 0.438 | Carcinogencity: | 0.082 |
Eye Corrosion: | 0.022 | Eye Irritation: | 0.145 |
Respiratory Toxicity: | 0.272 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003803 | 0.658 | D0S0NK | 0.293 | ||||
ENC005585 | 0.606 | D04VIS | 0.252 | ||||
ENC003421 | 0.487 | D04QNO | 0.230 | ||||
ENC002494 | 0.374 | D0Y7IU | 0.230 | ||||
ENC003295 | 0.358 | D02JNM | 0.228 | ||||
ENC005922 | 0.333 | D08PIQ | 0.225 | ||||
ENC003214 | 0.317 | D0P1FO | 0.221 | ||||
ENC002493 | 0.302 | D0D1SG | 0.219 | ||||
ENC002922 | 0.297 | D0Y2YP | 0.216 | ||||
ENC005685 | 0.292 | D0V9DZ | 0.216 |